Found: 34
Select item for more details and to access through your institution.
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition.
- Published in:
- Oncogene, 2010, v. 29, n. 16, p. 2325, doi. 10.1038/onc.2009.510
- By:
- Publication type:
- Article
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
- Published in:
- Leukemia (08876924), 2015, v. 29, n. 9, p. 1918, doi. 10.1038/leu.2015.83
- By:
- Publication type:
- Article
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
- Published in:
- 2015
- By:
- Publication type:
- letter
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
- Published in:
- Leukemia (08876924), 2015, v. 29, n. 2, p. 510, doi. 10.1038/leu.2014.300
- By:
- Publication type:
- Article
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
- Published in:
- Leukemia (08876924), 2014, v. 28, n. 3, p. 680, doi. 10.1038/leu.2013.231
- By:
- Publication type:
- Article
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).
- Published in:
- Leukemia (08876924), 2014, v. 28, n. 3, p. 525, doi. 10.1038/leu.2013.350
- By:
- Publication type:
- Article
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.
- Published in:
- Leukemia (08876924), 2014, v. 28, n. 2, p. 457, doi. 10.1038/leu.2013.301
- By:
- Publication type:
- Article
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 4, p. 780, doi. 10.1038/leu.2012.336
- By:
- Publication type:
- Article
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 5, p. 1153, doi. 10.1038/leu.2012.15
- By:
- Publication type:
- Article
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 4, p. 595, doi. 10.1038/leu.2011.346
- By:
- Publication type:
- Article
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.
- Published in:
- Leukemia (08876924), 2012, v. 26, n. 1, p. 149, doi. 10.1038/leu.2011.196
- By:
- Publication type:
- Article
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
- Published in:
- 2010
- By:
- Publication type:
- journal article
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
- Published in:
- 2009
- By:
- Publication type:
- journal article
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
- Published in:
- Leukemia (08876924), 2009, v. 23, n. 10, p. 1716, doi. 10.1038/leu.2009.122
- By:
- Publication type:
- Article
Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men.
- Published in:
- 1991
- By:
- Publication type:
- journal article
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
- Published in:
- British Journal of Haematology, 2004, v. 127, n. 2, p. 165, doi. 10.1111/j.1365-2141.2004.05188.x
- By:
- Publication type:
- Article
Defibrotide Blunts the Prothrombotic Effect of Thalidomide on Endothelial Cells.
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2012, v. 18, n. 1, p. 79, doi. 10.1177/1076029611412367
- By:
- Publication type:
- Article
Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 8, p. 1024, doi. 10.1038/bmt.2015.83
- By:
- Publication type:
- Article
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
- Published in:
- Bone Marrow Transplantation, 2008, v. 41, n. 3, p. 229, doi. 10.1038/sj.bmt.1705899
- By:
- Publication type:
- Article
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
- Published in:
- Leukemia (08876924), 2009, v. 23, n. 5, p. 961, doi. 10.1038/leu.2008.378
- By:
- Publication type:
- Article
The research mission in myeloma.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
- Published in:
- Leukemia (08876924), 2008, v. 22, n. 10, p. 1925, doi. 10.1038/leu.2008.174
- By:
- Publication type:
- Article
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
- Published in:
- 2008
- By:
- Publication type:
- Correction notice
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
- Published in:
- Leukemia (08876924), 2008, v. 22, n. 4, p. 842, doi. 10.1038/sj.leu.2405087
- By:
- Publication type:
- Article
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
- Published in:
- Leukemia (08876924), 2008, v. 22, n. 2, p. 414, doi. 10.1038/sj.leu.2405062
- By:
- Publication type:
- Article
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway.
- Published in:
- Leukemia (08876924), 2007, v. 21, n. 3, p. 535, doi. 10.1038/sj.leu.2404561
- By:
- Publication type:
- Article
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
- Published in:
- Leukemia (08876924), 2007, v. 21, n. 1, p. 151, doi. 10.1038/sj.leu.2404442
- By:
- Publication type:
- Article
A Receptor-Like Inositol Lipid Phosphatase Is Required for the Maturation of Developing Cochlear Hair Bundles.
- Published in:
- Journal of Neuroscience, 2003, v. 23, n. 27, p. 9208, doi. 10.1523/JNEUROSCI.23-27-09208.2003
- By:
- Publication type:
- Article
Routine screening for psychosocial distress following hematopoietic stem cell transplantation.
- Published in:
- Bone Marrow Transplantation, 2005, v. 35, n. 1, p. 77, doi. 10.1038/sj.bmt.1704709
- By:
- Publication type:
- Article
Ixazomib-induced cutaneous necrotizing vasculitis.
- Published in:
- Supportive Care in Cancer, 2018, v. 26, n. 7, p. 2247, doi. 10.1007/s00520-018-4052-1
- By:
- Publication type:
- Article
Ixazomib-induced cutaneous necrotizing vasculitis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Reduced climbing and increased slipping adaptation in cochlear hair cells of mice with Myo7a mutations.
- Published in:
- Nature Neuroscience, 2002, v. 5, n. 1, p. 41, doi. 10.1038/nn784
- By:
- Publication type:
- Article